Publicacions en col·laboració amb investigadors/es de Universidad Miguel Hernández de Elche (66)

2024

  1. In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug

    Pharmaceutics, Vol. 16, Núm. 3

  2. Pharmaceutical Compounding in Veterinary Medicine: Suspension of Itraconazole

    Pharmaceutics, Vol. 16, Núm. 5

2022

  1. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen

    International Journal of Pharmaceutics, Vol. 614

2020

  1. Candesartan cilexetil in vitro–in vivo correlation: Predictive dissolution as a development tool

    Pharmaceutics, Vol. 12, Núm. 7, pp. 1-21

  2. New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 18, pp. 1-30

2019

  1. Covalently crosslinked organophosphorous derivatives-chitosan hydrogel as a drug delivery system for oral administration of camptothecin

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 136, pp. 174-183

  2. Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

    Molecular Pharmaceutics, Vol. 16, Núm. 6, pp. 2418-2429

  3. Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug

    International Journal of Pharmaceutics, Vol. 557, pp. 36-42

2018

  1. Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Rat—Biophysical Model and Predictions Based on Caco-2

    Pharmaceutical Research, Vol. 35, Núm. 1

  2. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter

    European Journal of Pharmaceutical Sciences, Vol. 117, pp. 193-203

  3. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation

    European Journal of Pharmaceutical Sciences, Vol. 119, pp. 200-207

  4. Functional magnetic mesoporous silica microparticles capped with an azo-derivative: A promising colon drug delivery device

    Molecules, Vol. 23, Núm. 2

  5. Ionic Hydrogel Based on Chitosan Cross-Linked with 6-Phosphogluconic Trisodium Salt as a Drug Delivery System

    Biomacromolecules, Vol. 19, Núm. 4, pp. 1294-1304

  6. Long-circulating hyaluronan-based nanohydrogels as carriers of hydrophobic drugs

    Pharmaceutics, Vol. 10, Núm. 4

  7. PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen

    European Journal of Pharmaceutical Sciences, Vol. 115, pp. 119-125

  8. Preclinical models for colonic absorption, application to controlled release formulation development

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 130, pp. 247-259

  9. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits

    European Journal of Pharmaceutical Sciences, Vol. 120, pp. 123-132

  10. Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: New approaches for inflammatory bowel diseases treatment

    Journal of Controlled Release, Vol. 281, pp. 58-69

2017

  1. Comparison of segmental-dependent permeability in human and in situ perfusion model in rat

    European Journal of Pharmaceutical Sciences, Vol. 107, pp. 191-196

  2. Enhancing Oral Absorption of β-Lapachone: Progress Till Date

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 42, Núm. 1